EPISODE SUMMARY:
"Dr. Hyder Khoja, a visionary in the field of molecular drug discovery and psychedelic medicine, has been exploring the therapeutic potential of various psychotropic compounds to revive unconscious individuals.
On the Happy Spot podcast, Dr. Khoja discusses his research on ""Comatose Resurrection Therapy,"" which aims to enhance treatments for coma patients by studying the association of neurotransmitters with brain receptors."
"Dr. Hyder Khoja joins The Happy Spot podcast to discuss his groundbreaking research on Comatose Resurrection Therapy, a novel approach exploring how psychedelic medicine might help revive individuals from unconscious states. With a background in molecular drug discovery, Dr. Khoja examines how specific psychoactive compounds interact with brain receptors to stimulate neural activity in coma and traumatic brain injury (TBI) patients. His journey into this research began as a deeply personal one—confronting treatment choices for his mother’s brain tumor—leading him to investigate how altered states of consciousness might hold the key to restoring lost cognitive function.
In this episode, Dr. Khoja challenges conventional neuroscience by advocating for a more holistic approach to understanding the brain and human identity itself. From memory loss to disorders of consciousness, he explores the untapped therapeutic potential of psychedelics in reshaping how we treat severe neurological conditions. As he discusses cutting-edge findings and the ethical considerations surrounding his work, listeners will gain insight into the future of mental health, brain injury recovery, and the possibilities that lie at the intersection of neuroscience and psychedelics.
https://www.linkedin.com/in/scienceimpersario/
https://psychedelicspotlight.com/psychedelics-coma-patients/
https://www.instagram.com/redyhajohk/
https://academic.oup.com/nc/article/2019/1/niz003/5475888"
#ComaRecovery #PsychedelicMedicine #Neuroscience #BrainHealing #MentalHealth #ComatoseResurrection #TBIRecovery #PsychedelicTherapy #Neuroplasticity #FutureOfMedicine #DrHyderKhoja #TheHappySpot #ConsciousnessResearch #MindScience #MedicalBreakthroughs
In this thought-provoking episode of The Happy Spot, guest host Gaetano Lardieri welcomes visionary researcher Dr. Hyder Khoja to explore how psychedelics could potentially reignite consciousness in coma patients. Drawing from decades of scientific experience in plant biotechnology and neuroscience, Dr. Khoja explains how compounds like psilocybin and DMT may trigger neuroplasticity—helping the brain "rewire" itself and restore cognitive function. Backed by groundbreaking studies from institutions like Imperial College London, this conversation offers a hopeful glimpse into how nature's medicine might unlock new levels of healing and awareness.
In this powerful segment of The Happy Spot, Dr. Hyder Khoja opens up about the ethical and scientific hurdles in using psychedelics to treat coma patients, including challenges around patient consent and regulatory barriers. He emphasizes that collaboration among researchers, families, and policymakers is essential to bring hope to those in seemingly irreversible states—especially when traditional medicine has run out of options. Motivated by his own mother’s near-comatose experience, Dr. Khoja’s work blends compassion, personal conviction, and deep scientific knowledge to explore how plant-based compounds might help revive consciousness and renew life.
In this enlightening segment of The Happy Spot, Dr. Hyder Khoja shares his vision for using advanced tools like AI and partnerships with top universities to develop coma resurrection therapy—transforming what we now call “miracles” into real, scientific breakthroughs. Through his company, Transcendent Life Sciences, he hopes to bring hope and healing to families by restoring consciousness in coma patients using psychedelic compounds known to reset neural circuits. By combining cutting-edge research, ethical care, and personal passion, Dr. Khoja paints a future where even the most extreme states of unconsciousness may one day be reversible.
In the final segment of The Happy Spot, Dr. Hyder Khoja shares how transitioning psychedelic coma therapy from theory to practice requires rigorous trials, strong ethical frameworks, and collaboration with trusted institutions. He emphasizes that healing doesn't stop with waking up—ongoing support, nurturing environments, and community involvement are vital for long-term recovery and happiness. Listeners are encouraged to spread awareness, support research, and advocate for change so that what seems like a miracle today may become a transformative, hope-filled reality for countless families tomorrow.
00:00:39.930 --> 00:01:02.169 Gaetano Lardieri FUNGGUY: Welcome to the happy spot Podcast on Talkradio Dot, Nyc. Sponsored by Jack Thomas. I'm your special guest host, Gaetano larderi. I'm a cannabis and psychedelics, researcher and advocate for many years and professionally as a consultant in these 2 spaces for the last 11 years. In this special podcast series, we'll dive deep into all things. Medical cannabis and psychedelics.
00:01:02.170 --> 00:01:24.589 Gaetano Lardieri FUNGGUY: exploring how these compounds can transform lives, reduce stigma and advance groundbreaking research, drawing from my experience and connections with advocates, scientists, therapists, industry leaders. I'll introduce you to some of the most fascinating innovative minds in cannabis, psychedelic science, medicine, research, insurance and beyond get ready for an eye-opening journey into these dynamic industries. And further.
00:01:24.630 --> 00:01:38.460 Gaetano Lardieri FUNGGUY: just a quick disclaimer. This podcast doesn't substitute for legal or medical advice. And we do not condone the illegal use of substances. Welcome to our 6 podcasts in this special series which will feature a special outstanding individual.
00:01:39.000 --> 00:01:40.960 Gaetano Lardieri FUNGGUY: Excuse me, individual
00:01:41.390 --> 00:02:02.300 Gaetano Lardieri FUNGGUY: and global impact visionary Dr. Haider. We are going to have an interesting and enlightening conversation with Dr. Heider about coma, resurrection, therapy, psychedelics, consciousness, and so much more before I go into asking questions. Please, Heider, introduce yourself, and tell us a little bit more about who you are and what you do in this very interesting space.
00:02:03.350 --> 00:02:22.090 Dr. Hyder A. Khoja, Ph.D.: Yeah, thank you so very much. Gatana, for introducing me and giving me chance to be on this podcast I come from a very diverse background. Most of my, you know, life career path has been in a bio industry, biotechnology, genetics, and you name plant sciences.
00:02:22.090 --> 00:02:35.250 Dr. Hyder A. Khoja, Ph.D.: And most of my influence was through this understanding of philosophy of the plant sciences, how they behave, and how they are so important in this environment, and how we can utilize those compounds that comes from those
00:02:35.250 --> 00:02:43.060 Dr. Hyder A. Khoja, Ph.D.: in a very therapeutic way, and I have trained in in France as a doctorate, and I had been training
00:02:43.060 --> 00:03:12.659 Dr. Hyder A. Khoja, Ph.D.: in the United States did my couple postdoctorate at Michigan State University, later on to Virginia, Tech and University of Wyoming, in Laramie, and lastly, before I left United States, I worked for us Department of Energy on the Algae Biodiesel Project. And most recently, after that, I moved to Canada. And now I'm settled here and we're doing work towards the psychoactive compound that comes from the plant sciences.
00:03:13.210 --> 00:03:15.090 Gaetano Lardieri FUNGGUY: Excellent where whereabouts in Canada.
00:03:15.920 --> 00:03:19.570 Dr. Hyder A. Khoja, Ph.D.: I live in Vancouver Metro, Vancouver, BC, yeah.
00:03:19.720 --> 00:03:27.920 Gaetano Lardieri FUNGGUY: Nice. So let's get right into it. So could you share your journey and explain how you became involved with coma resurrection? Can you.
00:03:27.920 --> 00:03:29.010 Dr. Hyder A. Khoja, Ph.D.: Absolutely
00:03:29.960 --> 00:03:55.110 Dr. Hyder A. Khoja, Ph.D.: sorry. Yeah, absolutely. My journey towards coma resurrection therapy began at a confluence of my academic interest in molecular biology and a deeply personal convictions to innovate in the field of medical therapeutics. So after years spent studying genetic engineering and neurobiology, I observed a persistent gap in the effective treatments for disorders of consciousness.
00:03:55.210 --> 00:04:05.809 Dr. Hyder A. Khoja, Ph.D.: This realization inspired me to harness the science and apply it to the medicine. Most enigmatic challenges resurrecting the conscious mind.
00:04:07.710 --> 00:04:15.160 Gaetano Lardieri FUNGGUY: Oh, that's interesting. And what motivated you to pursue this innovative treatment approach, using psychedelics for coma patients.
00:04:16.230 --> 00:04:41.870 Dr. Hyder A. Khoja, Ph.D.: Yeah. So you know, when I was looking into different areas of medicines and the availability of medicine around in this world, I look, there is a gap between the people who are in the coma or vegetative states, because these people are considered medically dead because their mind has stuck in some area, and after traumatic brain injury, or some sort of, you know injury in the brain, or have a trauma.
00:04:41.870 --> 00:05:08.249 Dr. Hyder A. Khoja, Ph.D.: The brain is not functional. So I said, there is something we should do in a medical area where we can revive these people, so that at least come back to life in a medical society. What we see is these people when they go through traumatic brain injury, and after a long depletion in the oxygen from the brain, they consider a complete dead person, and then that person or individual stays on the bed for almost a year or 2,
00:05:08.250 --> 00:05:31.890 Dr. Hyder A. Khoja, Ph.D.: but without any results, and eventually they pass out. So the idea was behind as to how we can bring something that these people should come up back to the life, and not necessarily, you know, reviving from the dead. But we know that the brain is somewhere stuck, but the body is functioning. How we can make that the connections back together. So they start revived and come to a conscious mind.
00:05:32.260 --> 00:05:37.973 Gaetano Lardieri FUNGGUY: And and just for people who don't know are these people with flat Eegs or no Eeg
00:05:39.530 --> 00:05:40.020 Dr. Hyder A. Khoja, Ph.D.: The.
00:05:40.020 --> 00:06:00.839 Dr. Hyder A. Khoja, Ph.D.: I think that they are mixed mix of everything, because what happened, what I feel is people who just have a temporary dementia, or people who just lost their memory for just temporarily, or even people who have a long term traumatic brain injury, like, for example, the person who is walking on the street had a gunshot, and the person who just fell
00:06:00.840 --> 00:06:24.030 Dr. Hyder A. Khoja, Ph.D.: due to playing in football with a high heat. There are 2 different circumstances. One was a structural damage in the brain, whereas the other is just fell due to the heat. So the reviving part for these people who got a you know not had a structure, damage is more prevalent, and we can revive them. But whereas the structure damage happened is hard for us to really bring the whole person back.
00:06:24.570 --> 00:06:27.230 Gaetano Lardieri FUNGGUY: So these are kind of different levels of coma state.
00:06:27.760 --> 00:06:30.810 Dr. Hyder A. Khoja, Ph.D.: Exactly. Yeah, at different stages of life. Yeah.
00:06:30.810 --> 00:06:37.490 Gaetano Lardieri FUNGGUY: Okay, so what scientific evidence supports the idea that psychedelics can effectively treat coma patients.
00:06:38.610 --> 00:07:02.200 Dr. Hyder A. Khoja, Ph.D.: Well, there, there are many others you know, situation where? You know the doctors, especially if you look into some studies in Imperial College of London. They have done the the resonic imaging where where they looked into the the brain of a person who was given the medicine as well, a person without the the psychedelics, and they saw there's a
00:07:02.200 --> 00:07:12.280 Dr. Hyder A. Khoja, Ph.D.: the huge traffic when they prescribe the Lsds to them. And what happens? The neural connectivity was so fast they started looking into it that what is happening?
00:07:12.280 --> 00:07:31.759 Dr. Hyder A. Khoja, Ph.D.: So what what psychedelics does basically is triggers, those you know, the transmitters which are kind of in silent mode, and divide and spark them. So they come to the connection, and they start moving forward with the with the consciousness. And that's the beauty of the psychedelics, or so-called the psychoactive compounds.
00:07:31.930 --> 00:07:38.800 Gaetano Lardieri FUNGGUY: So you're you're making these connections and you're assuming the coma patients, I guess, are. There's an effect. They're feeling this
00:07:39.160 --> 00:07:40.320 Gaetano Lardieri FUNGGUY: somatically.
00:07:41.120 --> 00:08:10.899 Dr. Hyder A. Khoja, Ph.D.: Yes, that's right. So what happened is in a general view. If you look at in our, in our old culture, like yourself and myself. We are in a normal form of speech right now. These people were like us, and they have got all the information in front of us. But at a certain point, because of the damage happened to the brain for any reason traumatic. They felt the information was stopped at that point, and whatever information they had in those they were in the folders like for us.
00:08:11.000 --> 00:08:38.970 Dr. Hyder A. Khoja, Ph.D.: our mental abilities, such that our informations are, you know, segregated in a different kind of folders. For example, if I want to talk about to you by my science, there's a science information that I have in my brain somewhere. But if you want to talk about my family. There's a family information somewhere. Now these people. What happened when the traumatic brain injury happened? These folders were mixed. It fell down on the floor. Now papers were mixed. Now they don't know what to respond when you ask a question. That's why they are in vegetative state
00:08:38.970 --> 00:08:48.060 Dr. Hyder A. Khoja, Ph.D.: when they speak, they don't know what to say, what they are looking at. They come off, forgot the information. Even the information is in the head. What we are trying to do that, bringing these
00:08:48.180 --> 00:08:57.999 Dr. Hyder A. Khoja, Ph.D.: neurotransmitters to connect in a proper wiring. I would say so once the wiring is correct, the information flow is good, and that's what we we are aiming for.
00:08:58.220 --> 00:09:02.390 Dr. Hyder A. Khoja, Ph.D.: You're helping them pick up the files again and reorder them, I guess. And for.
00:09:03.300 --> 00:09:11.530 Gaetano Lardieri FUNGGUY: For the the medical people on, on the listening to the call. What technique do you use, Fmri? What what actual measurements do you use.
00:09:12.100 --> 00:09:34.560 Dr. Hyder A. Khoja, Ph.D.: Yeah. So I am more into the Fmr. Thingy, because the there was a there was a study done at Imperial College of London by Dr. Robin Karen, who who started doing that, you know, resonant imaging into the brain, whereas I also work on some of the area of using this compound in the clinical stage, because
00:09:34.560 --> 00:09:46.330 Dr. Hyder A. Khoja, Ph.D.: by just putting the gadget it doesn't mean that you get an answer, but by administering is the one that we will look for. And once we have that treatments, once we see that there's a result coming, and there's a change
00:09:46.330 --> 00:09:55.779 Dr. Hyder A. Khoja, Ph.D.: based on their studies. And also the John Hopkins University doing a lot of psychedelic work based on the collaborative efforts. I think we can come up with an idea, with a study.
00:09:55.780 --> 00:10:01.990 Dr. Hyder A. Khoja, Ph.D.: a proclaimed study that can go further to really find out the the answer for these treatments.
00:10:02.700 --> 00:10:08.309 Gaetano Lardieri FUNGGUY: And which psychedelic compounds, do you believe are most promising for treatment? And why.
00:10:09.220 --> 00:10:34.980 Dr. Hyder A. Khoja, Ph.D.: Yeah, I am more a fight of the you know. There are many psychedelic compounds, right? And psychedelic doesn't mean that. 1st of all, let me tell you what psychedelic and psychotropic compounds are, because there's a mix of a lot of information. Sometimes people think that psychedelic is a psychotropic. But what happens? Psychedelic is a science where we use the psychotropic compounds to treat, whereas the psychotropic is a compound itself. Now.
00:10:35.170 --> 00:11:04.189 Dr. Hyder A. Khoja, Ph.D.: in the event, we know that whatever molecules we get from the plants has a lot of value into humans. For example, if you take, eat, garlic, it has this leucine enzyme that helps in your heart. If you eat turmeric, it helps you inflammation in your same kind of company. If you eat tomato, it has a lycopene enzyme into it, helping prostate cancer. But we don't know. We don't necessarily have to have a cancer in order for that. But what we are trying to said. We
00:11:04.190 --> 00:11:20.120 Dr. Hyder A. Khoja, Ph.D.: know that these compounds exist in different plants coming to psychedelics. There's a list of all chemicals. Some are Dmt, some are Lsd, some are Psilocybin. What I'm interested in more of organic based. So psilocybin that comes from a magic mushroom
00:11:20.140 --> 00:11:30.960 Dr. Hyder A. Khoja, Ph.D.: and those compounds and plus the Dmt. The dimethyltin amide. Those are the more you know, favored compounds that I'm looking to for my studies.
00:11:31.780 --> 00:11:38.699 Gaetano Lardieri FUNGGUY: Excellent, excellent. And how do? How do these psychedelics potentially jumpstart consciousness in coma patients.
00:11:39.850 --> 00:12:09.130 Dr. Hyder A. Khoja, Ph.D.: Yeah. So what happened is, if you, if you look into, I give you a very layman analogy for that to for the general public audience to look at when we have a. When you sit in the car, and the purpose of our car is to go start the engine. We put the key in. We do the ignition, the igniting happened. The the spark goes into the fuel and fuel go into the engine and spark. What we are looking here. How it jumpstart is basically a reset button that it has. So when you
00:12:09.190 --> 00:12:29.199 Dr. Hyder A. Khoja, Ph.D.: administer these kind of compounds, they go into your neural and then find out where exactly the neurotransplicity is kind of breakdown, and at that point it sparks that area, and then, you know, change the phenomena of the conscious mind, unconscious mind become conscious at that time, or the transmitter started having a traffic.
00:12:29.250 --> 00:12:50.739 Dr. Hyder A. Khoja, Ph.D.: and where I see is analogy of is a car engine. How to start. I see that this is what we are trying to do, that we would like to use those compounds towards those neurons, neurotransmitters to connect with the other transmitters. So neurotransplicity happens, and then, you know, it revived the brain from from where it was stopped.
00:12:51.250 --> 00:12:58.189 Gaetano Lardieri FUNGGUY: Yeah. So you mentioned neuroplasticity, can you explain a little bit more about what neuroplasticity is actually.
00:12:58.850 --> 00:13:15.300 Dr. Hyder A. Khoja, Ph.D.: Yeah, the neurotransmi. You know, neurotransmitters that we have in the brain. Basically, there are millions of neurotransmitters all over in the brain. And then what happened is they are communicating with each other right now, when we are speaking to each other, they are communicating, and they are firing. If you look into your brain.
00:13:15.300 --> 00:13:37.749 Dr. Hyder A. Khoja, Ph.D.: We'll figure out there's so much traffic, and we don't know what is happening with all our communicating my my motor work that I'm doing my moving my hands, or I'm talking to you or looking the eye somewhere. Here all are connected. All are transmitting. And what is happening is the neurotransplicity gives you a leverage of those transmitters to connect to each other and communicate in the right directions.
00:13:37.750 --> 00:13:54.479 Dr. Hyder A. Khoja, Ph.D.: So while you know, if you want to drive from from California to San Jose or some places you need to have a roadmap. So these neurotransplicity basically help you navigate to the right track and go to the places. That's an analogy that I give for the brain.
00:13:55.400 --> 00:14:05.470 Gaetano Lardieri FUNGGUY: Okay, fantastic. So we're going to go to break. And then when we come back, we'll talk to Haider about challenges that researchers have facing psychedelics in coma patients. So let's go to break, and we'll be back in 2 min.
00:14:05.910 --> 00:14:06.340 Dr. Hyder A. Khoja, Ph.D.: Sure.
00:15:51.070 --> 00:16:07.220 Gaetano Lardieri FUNGGUY: Welcome back to Talkradio, dot Nyc. I'm your special host, Gaetano Arduiri, and we're here talking Dr. Haider. So, Dr. Heider, just before we went to break. Let's talk about what challenges do researchers face when studying the efficacy of psychedelics for treating coma patients.
00:16:07.910 --> 00:16:34.829 Dr. Hyder A. Khoja, Ph.D.: Yeah, it's very challenging, as it includes the limited accessibility of the patients in comatose states for clinical trials, ethical concerns regarding informant concerns and regulatory barriers that restrict the psychedelic research at the moment. Furthermore, designing this study, based on the above challenges to collect the data and accurately measure the consciousness. Recovery is inherently complex.
00:16:36.430 --> 00:16:45.570 Gaetano Lardieri FUNGGUY: Yeah, you know. So how? How do you get someone to sign up for a clinical trial? I guess there's a family member that has power of attorney. How does that? What's that process like.
00:16:46.120 --> 00:17:12.839 Dr. Hyder A. Khoja, Ph.D.: So I think the most part is like a collaboration. So when you have a collaboration is basically a key for this, like, if you have a working with the regulatory agencies, establishing an international research networks and utilizing the advanced imaging technologies like you mentioned earlier, we can design the robot studies and implementing the ethical frameworks to involve the patients. Families in the decision making can mitigate the concerns.
00:17:13.579 --> 00:17:20.470 Gaetano Lardieri FUNGGUY: That's right. Okay, so how can the medical and scientific community overcome these challenges to advance the research.
00:17:21.500 --> 00:17:40.720 Dr. Hyder A. Khoja, Ph.D.: Yeah, that's like I just mentioned. The collaboration is the key, but the same time is advocating in the right place where it's necessary. Now the thing is, these patients are in coma. They don't write to consent at this point, and the issue is that the family needs to come up and say, Well, our patient is already dying. Why don't we give a consent to
00:17:40.720 --> 00:18:03.509 Dr. Hyder A. Khoja, Ph.D.: someone who's really want to revive them back? And the problem is that the advocacy between the agencies will allow that consent needs to be eased once that is eased, then the family can easily consent that. Yes, go ahead and do the treatments because they don't have any other hope. All they hope they have either go for it or not, go for it, and let the patient die or revive them.
00:18:03.510 --> 00:18:21.969 Dr. Hyder A. Khoja, Ph.D.: So I think the collaborative efforts between the advocacy, you know departments, the policymakers as well as the medical team, needs to sit together to come up with these profound compound applications into the therapeutic potential of these unconscious mind and not necessary. Again.
00:18:22.470 --> 00:18:39.509 Dr. Hyder A. Khoja, Ph.D.: we are not just at the moment I'm looking in consciousness, but psychedelic or psychotropic compounds and application in many other areas like Ptsd and mental health and depression has been doing breakthrough work. So why don't we also apply that to these people who are actually in need.
00:18:40.410 --> 00:18:49.379 Gaetano Lardieri FUNGGUY: Yeah. So could you also elaborate on the ethical considerations involved in administering psychedelics to coma patients.
00:18:50.030 --> 00:19:15.859 Dr. Hyder A. Khoja, Ph.D.: Yeah. Administrating psychedelics to well numbered population raises important ethical questions, as we all know about the consent and patient autonomy engaging families and ethic boards in the decision-making process, ensuring the treatments, aligns with the patients with best interest while adhering the highest ethical standards that should be the key. In order for these kind of studies to promote.
00:19:16.160 --> 00:19:28.549 Gaetano Lardieri FUNGGUY: It's always about respect for the patients, the families, I agree, 100%. And how does how does the concept of brain death differ from your perspective. As a scientist.
00:19:29.280 --> 00:19:51.050 Dr. Hyder A. Khoja, Ph.D.: Yeah, from my perspective, you know, on an overall basis, the brain death represent an irreversible secessions of a brain function distinct from other disorders of the consciousness where potential for recovery remains. You know, I view brain as a dynamic system with the untapped capacity for repair.
00:19:51.398 --> 00:20:12.329 Dr. Hyder A. Khoja, Ph.D.: Even in seemingly dire circumstances. So the brain has. Is it engulfed in a skull, but has a capability like when you, when we are young, we see the young kids, we say, give them all the information, languages, skills, and all because the brain is like Sponge is working for that purpose and getting all the information. And really.
00:20:12.650 --> 00:20:17.069 Dr. Hyder A. Khoja, Ph.D.: you know, making that individual in a very pro, you know, profound way.
00:20:17.260 --> 00:20:47.079 Dr. Hyder A. Khoja, Ph.D.: the idea behind these that brain still is same. Even though we grow medically, we say that there's no importance after the certain knowledge is still been given. But throughout our life we can get the skills and knowledge, and the brain has the capability of putting those information. We get millions and billions of information every day. Whatever we see on the road by looking in the through the eyes. We capture all the information, but the only the necessary information which was told you will register.
00:20:47.080 --> 00:21:02.140 Dr. Hyder A. Khoja, Ph.D.: So let me give you another analogy which is gonna really highlight for the audience is, for example, if I would have to say to you that when you come to New York, or you have to say to me when you come to New York. Please go through that bridge. Of
00:21:02.440 --> 00:21:27.970 Dr. Hyder A. Khoja, Ph.D.: that you have over there very well known. What do you call the Brooklyn bridge and look around and tell me when you come back. So when you come back you ask me a question. When I come back you ask me a question. What did you see? The answer would be, I saw, you know, beautiful waterfalls, water area rivers, and looked at big buildings and kind of, you know in many, 5, 6 min I will tell you everything. But if you have to ask me that question.
00:21:28.000 --> 00:21:40.689 Dr. Hyder A. Khoja, Ph.D.: did you count the number of cars while you were driving, or did you register the number of colors or color of the cars while you were driving? Did you see how many people were walking on the bridge at that side at the sidewalks.
00:21:40.690 --> 00:22:00.840 Dr. Hyder A. Khoja, Ph.D.: I would never. I might give you an answer, but it will be an average answer. I might say I saw 10 people, but they must be 5 only I saw 100 cars, but there could be a thousand scars going through at that time. While I was going through, and the color I would not remember the reason being because now I tuned your mind to focus only the scenic view.
00:22:00.890 --> 00:22:18.450 Dr. Hyder A. Khoja, Ph.D.: I did not tune you for counting the cars. That's what happens in these kind of brain, you know the people get the information through. But they registered somewhere. Now, what happened. These unnecessary information is also in your brain. But when traumatic brain injury happens, these all are mixed up, and they don't know what to say what to do.
00:22:19.000 --> 00:22:32.680 Gaetano Lardieri FUNGGUY: Interesting, and you said something that made me think I want to ask you another question here, any different when you're given these psychedelic sarcoma patients, any difference between male female responses and actually children and adults? Any difference there that you see.
00:22:33.340 --> 00:22:57.860 Dr. Hyder A. Khoja, Ph.D.: This is this is really a critical question. Yes, for example, the the behavioral impact also counts of the emotions. For example, the I mean, of course, we all are humans. The the amount of efficacy of these compounds would be similar to anyone but the basis of the the age limit the mind itself. Also, the emotional behaviors that we carry for women's is a different kind of harm.
00:22:57.860 --> 00:23:05.129 Dr. Hyder A. Khoja, Ph.D.: emotional balances, whereas a man says, Well, now, let me tell you one thing. If the traumatic brain injury happens
00:23:05.140 --> 00:23:26.020 Dr. Hyder A. Khoja, Ph.D.: right now, for example, for any accident happen, and we pick up and paramedic, come and administer them. Medicine, it would be quicker response to that comparatively person who is already there for a week in the bed. And now you're coming to be administered, the reason being because the brain has probably depleted their cells, are dying. So at the right moment.
00:23:26.020 --> 00:23:50.929 Dr. Hyder A. Khoja, Ph.D.: you know, the treatment at the right movement is given is the key same for the the different age group and as well as gender. I don't think gender is a more of make a difference, but for the for the amount of the of the age differences that would really matter, because brain has some. You know, brain has a timings in which it has its own capacity to heal itself.
00:23:50.930 --> 00:24:06.230 Dr. Hyder A. Khoja, Ph.D.: And in many circumstances it's so important. When we administer, we want to make sure those those trials and tests are not just done in the general population, but within the general population segregate to general environment. So that's important piece. Yes, thanks for asking that question.
00:24:06.370 --> 00:24:19.839 Gaetano Lardieri FUNGGUY: Yes, definitely. You definitely want a diverse population to have your clinical trial study. And absolutely, I agree. And so can you describe any personal experiences that influence your dedication to developing coma, resurrection, therapy.
00:24:20.580 --> 00:24:28.729 Dr. Hyder A. Khoja, Ph.D.: Yeah, actually, I have my personal you know. Witness my mother. She has a managing tumor in 2,013.
00:24:28.730 --> 00:24:58.329 Dr. Hyder A. Khoja, Ph.D.: The tumor was so big, like a golf-sized ball, but it was managing. It was not cancer, and they took out the tumor after 16 h of surgery, but she could not wake up after 3 weeks close to 3 and a half weeks of timings, and we did not understand what happened, but when she woke up. She was not able to either see us properly or register what she's saying. And the same time she was not able to really response
00:24:58.330 --> 00:25:15.590 Dr. Hyder A. Khoja, Ph.D.: her feeding, you know, eating ability has, you know, gone. Perception has seeing ability was very diminished. So what I looked into it that I mean she'd become a part of this same theory that I'm working on the coma because she'd been
00:25:15.590 --> 00:25:33.520 Dr. Hyder A. Khoja, Ph.D.: sort of induced. Now, I mean, it wasn't meant for we wanted to come back as a normal person, because she all she had is a strokes when she had a strokes multiple times during a month. That's the time we took it to a doctor and doctor realized that she might have a tumor.
00:25:33.520 --> 00:25:50.110 Dr. Hyder A. Khoja, Ph.D.: and we need to have a tumor removed. She was healthy person, but all she has a tumor. Once she removed, this thing happened. So I can see in these kind of thing. These are induced sort of coma that happens, and in many cases people do come with that, and some are natural coma.
00:25:50.110 --> 00:26:09.620 Dr. Hyder A. Khoja, Ph.D.: I would say, you know that that witnessing that moms and emotion you know thing that gone through. You know, I felt that it's a it's a it's a time that I should think about it and go into this more in a research base. And hopefully one day, you know this research can, you know, profoundly help for other people?
00:26:09.930 --> 00:26:19.070 Gaetano Lardieri FUNGGUY: Yeah, and thank you for that research. So, and how did your background in molecular biology and genetic engineering contribute to your current work?
00:26:21.068 --> 00:26:37.569 Dr. Hyder A. Khoja, Ph.D.: Yeah. So you know, I come from a very like I said diverse, you know, skill set. So I trained as a plant biologist. I've been in plant physiology. Then I did a cytogenetics in the plants. Then I went to molecular biology and genetic engineering.
00:26:37.570 --> 00:26:53.449 Dr. Hyder A. Khoja, Ph.D.: Now, molecular biology is a bigger head name, I would say a title underneath the genetic engineering cytogenetics. And there are many other biochemistry, and I'm sure you know an audience know that the idea behind the engineering part as well as the molecular part.
00:26:53.560 --> 00:27:15.609 Dr. Hyder A. Khoja, Ph.D.: Help me because you can look into the cells profile. You can look at the DNA and gene profile. Now we are not saying here that we're going to genetically alter the gene so it can behave properly or become a but what we are saying that my experience in those areas have helped me, you know, go through understanding of different kinds of compounds that could help
00:27:15.650 --> 00:27:43.510 Dr. Hyder A. Khoja, Ph.D.: to revive or ignite those molecules which are which are present in humans. And you know the receptors that we have in our brain. I mean the serotonin receptors. Cb, one receptors, and those receptors are aligned, and ignite, or kind of a start as a jump start when the molecules are triggered to the right space. You know, once they do that things really come to, you know, in a uniformity.
00:27:43.560 --> 00:27:49.510 Dr. Hyder A. Khoja, Ph.D.: And my molecular work and genetic engineering really helped me understand that philosophy. That's why I'm
00:27:49.580 --> 00:27:52.129 Dr. Hyder A. Khoja, Ph.D.: I'm here to actually explain it to you.
00:27:52.440 --> 00:27:59.269 Gaetano Lardieri FUNGGUY: That's excellent. And and I believe this. Isn't it correct? The Cb. One receptors are just in the brain stem, or are they.
00:27:59.660 --> 00:28:25.279 Dr. Hyder A. Khoja, Ph.D.: Yeah. So the Cb, yeah. Cb, one, and Cb, 2, cb, 2 is more of a related. It's still they are in the brain, but they still they govern the more of a nervous system, as of the body system, whereas Cb, one is more of a brain engulf. So when we talk about different psychoactive compounds. I just have to name it here, for example, cannabinoids in such cases that triggers is act like a key
00:28:25.514 --> 00:28:31.599 Dr. Hyder A. Khoja, Ph.D.: for the lock, which is kind of locked in the Cb. One. So cb, one considers a lock and we need a key to open it.
00:28:31.600 --> 00:28:52.200 Dr. Hyder A. Khoja, Ph.D.: and same for Cb. 2. So we do have different kind of receptors in the brain. One of the receptors serotonin, and some of the molecules, for example, psychedelics, especially psilocybin, has a similar structure as the serotonin. That's why it's more easy for us to administer or profound, or look for that kind of research.
00:28:52.680 --> 00:29:01.149 Gaetano Lardieri FUNGGUY: Okay, and we're going to go to break when we come back. I want to ask Dr. Heider about AI and coma patients. So let's go to break, and we'll be back in a minute.
00:29:01.720 --> 00:29:02.200 Dr. Hyder A. Khoja, Ph.D.: Sure.
00:30:37.690 --> 00:30:45.899 Gaetano Lardieri FUNGGUY: Welcome back to Talkradio dot Nyc. I'm your special host, Gaetana Lardieri. We're here talking, Dr. Haider. So, Dr. Haider.
00:30:46.160 --> 00:30:53.820 Gaetano Lardieri FUNGGUY: there are certain tools that we use right? Like we mentioned Fmri Eeg. Do you use AI at all? Because that's another tool. Correct.
00:30:54.730 --> 00:31:06.730 Dr. Hyder A. Khoja, Ph.D.: Absolutely. Yes. So the answer to the question, no, at this moment. But the AI is one of the areas that I'm I'm looking at, too. So my my perception for AI is different than others. Maybe
00:31:06.820 --> 00:31:33.499 Dr. Hyder A. Khoja, Ph.D.: so, AI is a basically is a brand new tool that people been using now for everything. I mean, I would say, control life. It will control the life. AI. But the idea behind is missing is whatever you feed in AI AI will detect that. So, for example, you say, AI count one to 10, it will know, because we have said that how counting works to the AI. It's not coming from the nature to AI. We are. We are a human.
00:31:33.500 --> 00:31:47.919 Dr. Hyder A. Khoja, Ph.D.: and we are more intelligent to AI, so I call it human hai rather than AI. Human AI is more of a, you know, intelligent form of it. But coming back to your question, I think AI necessity has been getting really
00:31:47.920 --> 00:32:16.890 Dr. Hyder A. Khoja, Ph.D.: crucial. At this point there are many things that we can make work. AI has a tool also to predict in future what might happen. And that's people are looking at, for example, not necessarily the fat information, but it has a capability to look beyond that where human mind is still thinking about, it might go again much further as compared in the medical team, like nanotechnology and all those they are now using. AI. And I think at this moment to answer, for sure we are not yet
00:32:16.890 --> 00:32:46.549 Dr. Hyder A. Khoja, Ph.D.: we are looking forward to use that, but for sure, at the moment we are not ready for the AI system, because, 1st of all, there's so many other steps that we have to finalize, or we have to go through this for a particular particular research that I'm doing. I mean, if you talk about other area depression and anxiety, you can definitely detect AI tools that can look for the condition in a human and then can tell you, hey, we require this kind of medicine, and then you can go as an addition to for sure. AI is helping.
00:32:46.550 --> 00:33:00.050 Dr. Hyder A. Khoja, Ph.D.: But just to say, AI do this and make sure that it's working. I think it's still a little further, and the research needs to be done on that area. But for sure, AI will definitely help and speed up this process.
00:33:00.390 --> 00:33:13.749 Gaetano Lardieri FUNGGUY: Yeah, exactly. It's it's another tool to be used. And like you said, if you put crap in, you get crap out. So you got to be careful about because we're humans putting that information in, right? So just to move on, what are your goals for transcendent life sciences? Inc.
00:33:15.010 --> 00:33:25.799 Dr. Hyder A. Khoja, Ph.D.: Yeah, I am actually at transcendent life sciences. Our company goal is to pioneer the groundbreaking therapies for disorder, consciousness with coma resurrection therapy
00:33:25.880 --> 00:33:36.270 Dr. Hyder A. Khoja, Ph.D.: as our flagship initiative at this moment. Okay, we aim to create a future where awakening from a coma is not just a miracle, but a scientific reality.
00:33:36.330 --> 00:34:03.979 Dr. Hyder A. Khoja, Ph.D.: So at this moment, whenever you look for it, you say it's miracle happened. He came back to life. Okay, miracle do happen in many circumstances. But what what we can wait for miracles to happen, or it only happens to holy people. What we are looking is for a scientific you know, a relevancy to it. And that can you know, proof of concept that it gives to us for considering that for sure, it gonna work out. And we can try our best. So
00:34:03.980 --> 00:34:20.120 Dr. Hyder A. Khoja, Ph.D.: yeah, so at transient life sciences, we are looking into the groundbreaking work at this moment to just make sure the coma resecration therapy come to being. And then, once it happens, then you know, this could be a groundbreaking Nobel Prize winner, I would say. That's what I'm looking for.
00:34:20.429 --> 00:34:23.500 Gaetano Lardieri FUNGGUY: Absolutely. Oh, God bless you! And good luck with that right?
00:34:24.139 --> 00:34:27.339 Gaetano Lardieri FUNGGUY: So let me ask you, has anyone
00:34:27.709 --> 00:34:43.769 Gaetano Lardieri FUNGGUY: who's used these? You've ministered the psychedelics to, and they've woken up or coming out of the coma state. Have they had any visions or explain anything to you of seeing past lives? Yeah, maybe you can explain that because it is a hallucinogenic experience. Right?
00:34:44.469 --> 00:35:10.626 Dr. Hyder A. Khoja, Ph.D.: Excuse me. Yeah. So that that's a very interesting question. So let me give you 2 examples. One of the coma patient came back without administering, and other might have come by using some medicines. Okay. So in our medical term, we use, you know, when they are doing surgery, we use a medicine called Nbn Mbn is, you know one of the things that the doctor and surgeon, you know, who are
00:35:11.290 --> 00:35:26.129 Dr. Hyder A. Khoja, Ph.D.: a person who gives the you know, when you go for surgery they make you unconscious at the stage, and they want to wake you up afterwards. If you're not coming back to coming back to waking, and they give you this ambient medicine.
00:35:26.820 --> 00:35:27.320 Dr. Hyder A. Khoja, Ph.D.: The answer.
00:35:27.320 --> 00:35:28.490 Gaetano Lardieri FUNGGUY: Physiologist.
00:35:29.190 --> 00:35:45.090 Dr. Hyder A. Khoja, Ph.D.: Exactly so I want to. We are actually trying to compare that. What is the what is the threshold of that, and how much timings we require in order for them to revise. So that's 1 area, the other, like you mentioned about coma. The interesting things like there are people when they come back.
00:35:45.620 --> 00:35:53.429 Dr. Hyder A. Khoja, Ph.D.: So what happened is is very interesting. Hear me now, because the people who go in coma a traumatic brain injury.
00:35:53.580 --> 00:36:05.500 Dr. Hyder A. Khoja, Ph.D.: for example, they were driving. They hit by a car, but their damage was not that bad. They were just went to coma because the there was trauma was so bad, and they come back after a half an hour, or the paramedic comes.
00:36:05.610 --> 00:36:34.160 Dr. Hyder A. Khoja, Ph.D.: They do remember what happened because they were in the team that happened. People who just passed out, for some reason by stroke or by stress in their mind, for family or for any reason, and they go in the coma, and they come back afterwards. The situation is different, because when they come they either they've been to that certain stage. I don't know in many stages that they don't want to share you what exactly happened during that path, because
00:36:34.250 --> 00:36:51.419 Dr. Hyder A. Khoja, Ph.D.: either if they're very, you know, confidential for them, or been been told not to tell. I don't know what happened. I've heard a couple of people. They don't want to share what happened when they were gone, because the stage in which their mind was has become unconscious, and they come back.
00:36:51.520 --> 00:37:02.230 Dr. Hyder A. Khoja, Ph.D.: There was many things that happened. So if a person came back after 6 months or after a year, and in in there there, and we call it miracle, because that's a miracle. When they come back.
00:37:02.720 --> 00:37:24.859 Dr. Hyder A. Khoja, Ph.D.: They are aged, maybe a little bit a year old, and they were at that different mindset at that time they were going through a psychological issue, and that they fell into that. So they completely wiped out at that time when you ask them, or they don't want to tell you. But with the with the timings eventually they mix up, and they eventually tell you this story, but it's very.
00:37:24.860 --> 00:37:41.250 Dr. Hyder A. Khoja, Ph.D.: very different. So I see when psychedelics are treated or given or taken by people as a recreational or soothing, they have similar kind of effect that I've heard and learned that they have different experiences, especially Dmts. Dmt. Is very short
00:37:41.590 --> 00:38:03.739 Dr. Hyder A. Khoja, Ph.D.: taken, and it takes you towards that. You feel that you're out of body expression, that's what he call it. As so, I personally think there's a many areas that we have to focus. But scientifically, you know, reviving from this compounds. That's something that we would aim to come. Come with this kind of a research. I think that would be a key.
00:38:04.110 --> 00:38:21.190 Gaetano Lardieri FUNGGUY: Yeah, that's very interesting, because the hundreds of people, maybe thousands, that I've spoken to, you know, they always compare the experience of childbirth or something profound. Right? So that's interesting. But how do you plan to collaborate with universities and other institutions to develop coma, resurrection therapy.
00:38:21.950 --> 00:38:41.740 Dr. Hyder A. Khoja, Ph.D.: Yeah. So we intend to establish partnership with leading research universities, such as the one that I have in mind. And I'm in touch with John Hopkins University and Imperial College of London. Again. These are more profound when you Google it, they just pop up that they are doing research because they are ahead many years now. So those are the key.
00:38:41.740 --> 00:39:11.180 Dr. Hyder A. Khoja, Ph.D.: You know, university I'm focusing. But beside that, there are many in Europe that I have to look into that are working in psychedelics. So these 2, and leveraging their expertise in neurosciences and pharmacology to conduct the rigorous clinical trials and and also based on their, you know. Collaboration, we can do. The, you know, bring different academia as well. I mean, not necessarily these only 2 universities, and promote the development of this standardized treatment protocols.
00:39:11.340 --> 00:39:12.649 Dr. Hyder A. Khoja, Ph.D.: That's an idea.
00:39:12.920 --> 00:39:20.676 Gaetano Lardieri FUNGGUY: And and these are all research studies cause. So the physicians administering the psychedelics will have a schedule, one license. And it's all
00:39:21.000 --> 00:39:50.020 Dr. Hyder A. Khoja, Ph.D.: Yeah. So I think I have to come back to this point. For example, there are many like in health Canada. Here in Canada. We have health, Canada that administers the production and the research work of psychedelics to go through them, and they give you a license to that. For example, you want to grow magic mushrooms in your greenhouses on your store. You need to have a license. You need to have all, and the license is not easy. It's not like applying a driver's license. They have to come to your
00:39:50.020 --> 00:39:57.880 Dr. Hyder A. Khoja, Ph.D.: to your lab and going to see every restriction. How the chemical has been used how been treated, and once you grow that, for example.
00:39:57.880 --> 00:40:08.939 Dr. Hyder A. Khoja, Ph.D.: then they you are allowed to grow magic mushroom, or the psilocybin extraction for formulation. But the person they want to sell. That also needs to have a license on it to do that research. It's very.
00:40:08.940 --> 00:40:38.029 Dr. Hyder A. Khoja, Ph.D.: It's very stringent. It's not very easy, same for cannabinoid medical purposes, cannabis. When there's 1 for medical purposes, you need to go through licenses, and I'm pretty sure in us also, and many other parts of the world. They have the restriction body Health Ministry. They want to administer. That's why it's still under schedule. It's not fully given license to everybody, and they want to make sure that the licensors are well equipped with the treatments and all the protocols before they even apply for.
00:40:38.110 --> 00:40:39.280 Dr. Hyder A. Khoja, Ph.D.: So yeah.
00:40:39.820 --> 00:40:45.830 Gaetano Lardieri FUNGGUY: And what impact do you hope? Coma, resurrection therapy will have on patients and their families?
00:40:46.980 --> 00:41:06.530 Dr. Hyder A. Khoja, Ph.D.: I personally hope that this therapy transformed the narrative of glaucoma patients and their families, providing the pathways to recovery and alleviating the emotional and financial burden associated with the prolonged unconsciousness. The goal is to restore hope and redefine the possibilities.
00:41:07.240 --> 00:41:13.400 Gaetano Lardieri FUNGGUY: Excellent. And how does the potential of psychedelics in treating various psychopathologies intersect with your work.
00:41:14.690 --> 00:41:28.779 Dr. Hyder A. Khoja, Ph.D.: Yeah, so well, the growing evidence of psychedelics, efficacy in treating depression, Ptsd autism and addiction highlights their capacity to reset the neural circuits in the brain.
00:41:29.020 --> 00:41:39.040 Dr. Hyder A. Khoja, Ph.D.: These insight reinforce the possibility of using the psychedelics to stimulate the neural network in coma patients. Yeah, that's the idea that I gave you because
00:41:39.130 --> 00:41:57.529 Dr. Hyder A. Khoja, Ph.D.: our brain has all the neurons sitting, but because they are either they're firing information all over how you want to track it back to a rhythm, and once the rhythm is correct, then the information flow is good and the highway become clean, the traffic goes away, and then you can drive through. That's the that's the idea behind using.
00:41:57.882 --> 00:42:14.809 Dr. Hyder A. Khoja, Ph.D.: I mean, people are using like, I said, for depression, anxiety, Ptsd for military, and you know, defense, and even for people who are migrating from war zones like people are coming from Syria, people coming from wherever the war is happening migrating. They come with all this
00:42:14.940 --> 00:42:23.419 Dr. Hyder A. Khoja, Ph.D.: trauma and how you're going to do that, I think, yeah. So there's there's a lot of neural, you know, kind of work needs to be.
00:42:23.760 --> 00:42:24.970 Dr. Hyder A. Khoja, Ph.D.: Yeah, you're like.
00:42:25.140 --> 00:42:38.040 Gaetano Lardieri FUNGGUY: Traffic cop. You're clearing up all the traffic, and you're setting the lane straight again. So that's fantastic. Can you discuss the role of neural circuits, and their importance in consciousness.
00:42:38.910 --> 00:42:50.539 Dr. Hyder A. Khoja, Ph.D.: Yeah, sure. So the neural circuits form the architect of the consciousness by mediating the information, flow across the brain.
00:42:50.940 --> 00:43:02.560 Dr. Hyder A. Khoja, Ph.D.: and psychedelics can stimulate this circuit, increasing connectivity and promoting the brain's self organizing capacity, which is crucial for the conscious awareness.
00:43:03.870 --> 00:43:15.119 Gaetano Lardieri FUNGGUY: Excellent. Yeah. Okay, so we're going to go to break, and we'll back in 2 min, and then we'll talk to Haider about transitioning theoretical research into practical application. So let's go break, and we'll be right back.
00:44:53.570 --> 00:45:13.799 Gaetano Lardieri FUNGGUY: Welcome back to Talkradio, dot Nyc. I'm your special guest host, Gaetano Arduiri, and we're here talking to Dr. Haider about coma and psychedelics, and so many other wonderful things. Haider, let me ask you what steps are necessary to transition from theoretical research to practical application in this field.
00:45:15.200 --> 00:45:41.090 Dr. Hyder A. Khoja, Ph.D.: Basically, it requires the conducting extensive preclinical studies followed by phased clinical trials to assess the safety and efficacy that's the priority for sure number one priority it is, and then partnership with regulatory bodies and medical institutions will ensure that these therapies are both accessible and ethically sound.
00:45:42.660 --> 00:45:43.440 Dr. Hyder A. Khoja, Ph.D.: I think that's it.
00:45:43.440 --> 00:45:55.030 Gaetano Lardieri FUNGGUY: Right? Yeah, no, that's excellent. And are you going to, are you? What ongoing studies or clinical trials that align with your research on psychedelics and coma treatment. Currently.
00:45:55.630 --> 00:46:14.519 Dr. Hyder A. Khoja, Ph.D.: Yeah. There was a study published in Journal of Royal Society. Interference about that. Psychedelics expand the consciousness, and when mapped by the fmri functional magnetic resonance, imaging that you mentioned. They do, in fact, light up the neural signals.
00:46:14.520 --> 00:46:27.749 Dr. Hyder A. Khoja, Ph.D.: and in scientific language. If I would like to say, the psychedelic increases the complexity. This is one measure of consciousness and psychedelic, especially psilocybin and Dmt. Could alleviate
00:46:27.750 --> 00:46:42.959 Dr. Hyder A. Khoja, Ph.D.: the consciousness. Awareness in patients in a vegetative state and provide a foundation for us actually, and expanding this work and clinical trials. To include the comatose patients is a logical next step for us.
00:46:43.650 --> 00:47:01.839 Gaetano Lardieri FUNGGUY: Yeah. So it's like, it's like a reset. And I know when you're doing certain psychedelics, they replace it with therapy right after you given the medicine. Is there any replacement here? In other words, after they come out of that state? Is there any therapy or integration? That's part of the protocol.
00:47:02.620 --> 00:47:17.470 Dr. Hyder A. Khoja, Ph.D.: I think what we are looking is, you're right. The question is very good, you know, when my studies were doing in different researches, which I did was combination drug therapies. You know, when you have a medicine, for example, you have a cancer patient for Godbidden.
00:47:17.500 --> 00:47:36.939 Dr. Hyder A. Khoja, Ph.D.: And we were proposing compounds from cannabinoids using for cancer treatment. But the cancer patient normally lose their hairs. The appetite goes away because their actual healthy cells are dying, due to chemotherapy, and what we are doing is there's a combination of medicine that can be given through as an adjunct.
00:47:36.940 --> 00:48:03.490 Dr. Hyder A. Khoja, Ph.D.: a joint therapeutic for that cancer. It can reduce the hair fall, it can increase the appetite and patient feel healthy in this situation. I mean psychedelics. When you do, there's no side effects. Psychedelics. It's considered to be non-toxic. Any liver problem. There's nothing come with that. So metabolize very well, and it goes out from your system very quickly, so there's no side effects, such as but
00:48:03.510 --> 00:48:08.270 Dr. Hyder A. Khoja, Ph.D.: for the people in coma, if you treat them and they are coming back, I think the base
00:48:08.350 --> 00:48:35.199 Dr. Hyder A. Khoja, Ph.D.: remedy for them is how the family treat them at home. I mean the the way you bring them, making it. Make sure that they are coming to a right environment. They feel very comfortable, and that's, I think, for us would be like, I said. There's no side effect. There's no residual effect left after using these psychotropic compounds. That is the Major, you know a win for us that will helping these people not to go for another kind of combination.
00:48:35.520 --> 00:48:40.779 Dr. Hyder A. Khoja, Ph.D.: So you don't want to just give them the medicine and say goodbye. You want that support system afterward.
00:48:40.780 --> 00:48:43.100 Dr. Hyder A. Khoja, Ph.D.: Very important, very important. Yes.
00:48:43.130 --> 00:48:50.569 Gaetano Lardieri FUNGGUY: That's fantastic. And how do you envision the future coma, resurrection therapy, and its acceptance with within the medical community.
00:48:51.430 --> 00:48:58.359 Dr. Hyder A. Khoja, Ph.D.: Yeah, I I foresee the future where coma, resurrection therapy becomes the integral part of the critical care medicine
00:48:58.690 --> 00:49:16.410 Dr. Hyder A. Khoja, Ph.D.: supported by a robust body of evidence as an understanding grows, so will acceptance, transforming how we approach disorder of consciousness, and we aim to create a future where awakening from a coma is not a miracle, but a scientific reality. Like I mentioned earlier.
00:49:16.850 --> 00:49:27.449 Gaetano Lardieri FUNGGUY: Yeah, excellent. Yes, it will become a scientific miracle in the future. And how can the public and other stakeholders support your efforts and advance this innovative therapy.
00:49:28.610 --> 00:49:56.670 Dr. Hyder A. Khoja, Ph.D.: Yeah, there are quite a few areas that I need to tell about. So the the rising awareness. So that is one of them. So share information about the therapy through social media like you are doing community events like Go and present something advocacy group like go into policymaking to educate others about this potential benefits. That's number one second, most important would be building partnerships like collaborate with researchers.
00:49:56.670 --> 00:50:18.389 Dr. Hyder A. Khoja, Ph.D.: Same minded academia institutions and industries leaders to accelerate the development and streamline, the pathways to approval, funding and donations for sure contribute to research funding either directly or through fundraising initiatives to ensure the resources are available for the development and trials, such as you know.
00:50:18.390 --> 00:50:30.960 Dr. Hyder A. Khoja, Ph.D.: for many areas like cancer research and Alzheimer research, there's a funding and donation. I think this needs to be because it needs groundbreaking amount of money in order for for doing the groundbreaking work.
00:50:30.960 --> 00:50:49.749 Dr. Hyder A. Khoja, Ph.D.: participating in the clinical trials for sure, contribute to research funding, you know, eligible individuals can volunteer for clinical studies. Now you can ask me why eligible individuals who would be who going to give the consent for them? So again, the family would consent for them.
00:50:49.750 --> 00:51:00.980 Dr. Hyder A. Khoja, Ph.D.: It's not that they want to go in coma, but the people who are in coma. The families can then provide the consents helping to validate therapies, efficacy, efficacy, and safety. Like I mentioned
00:51:00.980 --> 00:51:18.570 Dr. Hyder A. Khoja, Ph.D.: advocacy lobby in policymakers for regulatory support, favorable legislations, or increase public funding for the therapy. I think lobbying is very important, especially through the tools like you are having the radio talks. Or you know, TV talks where
00:51:18.570 --> 00:51:42.279 Dr. Hyder A. Khoja, Ph.D.: people can listen and then consider that this is really a needed area, providing feedbacks, stakeholders like patients, caregivers, or healthcare providers can share their experiences and insights to refine and improve the therapy. We can invite those people once they come out from the consciousness, or the family who are going through that therapies at this moment come back and share their
00:51:42.280 --> 00:51:51.579 Dr. Hyder A. Khoja, Ph.D.: validation. So people say, Yeah, this is the area we are having benefits. Why don't you don't? Why don't you go and have a same treatment done for your individuals.
00:51:51.670 --> 00:52:18.799 Dr. Hyder A. Khoja, Ph.D.: encouraging and open dialogue. That's the most important part where you can bring those people like you have having interviews like, maybe you have 2, 3 people that can interact so open up foster discussion within the community to dispel the myths that we have that psychotropic or psychedelic going to harm you or kill you. Of course you're going to harm you anything. If you take salt, 3 spoons. If you take sugar to a spoon, you're going to kill you for sure. You need to have a moderation.
00:52:18.800 --> 00:52:29.660 Dr. Hyder A. Khoja, Ph.D.: and that's the key in heroine. You know, the heroine is addicted people. It can be used for medicine, but we are taking, or people are taking as an addiction.
00:52:29.670 --> 00:52:35.369 Dr. Hyder A. Khoja, Ph.D.: And psychedelic, in fact, is also as a addiction of secession, too. We can use that
00:52:35.590 --> 00:52:52.409 Dr. Hyder A. Khoja, Ph.D.: and build trust in the therapy. And I think these major areas, if it's covered confoundly by scientific body, academia and policymakers, it's not going to help only the humans, but also the whole States.
00:52:52.570 --> 00:53:13.420 Dr. Hyder A. Khoja, Ph.D.: I mean, if you come up and ask about how much tax you want to put on growth of this and how this I mean, there are many major concerns that might come up, and there's a policymaker can deal with that. But I think, as a scientist as a medical team or as an academia. There's a thirst for this, and we should bring that into the limelight
00:53:13.420 --> 00:53:32.430 Dr. Hyder A. Khoja, Ph.D.: through this kind of media that it's a necessity part of the of the overall daily going medical requirements. And just one last thing, I think, when you see these patients sitting in the bed for 2 years. How much amount of financial burden it has on the family. And
00:53:32.600 --> 00:53:55.259 Dr. Hyder A. Khoja, Ph.D.: honestly, I gone through families when they look, their patients are sitting there. Either they are very desperate. They're emotionally bad, or they will say just, they pray for God. Just take their life because they don't want them seeing dying like that rather than either coming to back to life, or just don't prolong that that long. It's a very financially and emotionally is burdensome.
00:53:56.190 --> 00:54:06.720 Gaetano Lardieri FUNGGUY: And that you mentioned that, are there any support groups for families, or I guess coma survivors afterwards? Are there any support groups you want to give a shout out to, or that are worth mentioning.
00:54:07.590 --> 00:54:28.089 Dr. Hyder A. Khoja, Ph.D.: Yeah, there are societies, Alzheimer's societies, dementia societies, I mean, I don't know exact names. But there, I mean, if you just pop up, we can just write Alzheimer dementia, I mean, those are the 2 which are connected to this. And then again, a mental, you know, association that can deal with these kind of situation where
00:54:28.120 --> 00:54:45.410 Dr. Hyder A. Khoja, Ph.D.: I mean, we can just say, Hey, this is the requirement. You people who are going through dementia. You can bring them to the board and the discussion. And what what one-on-one therapies! It's not like a therapy is a voluntary basis. What I'm going to say like you can bring them, ask them their time and tell them suit them
00:54:45.730 --> 00:55:03.239 Dr. Hyder A. Khoja, Ph.D.: in. You know, as we go older, currently we are young as we go older, the chances of us to get access is lower, because we are either you know, on the, on the care, on the, you know. Sometimes the medical care we are not having accesses to go, even though we speak sometime.
00:55:03.270 --> 00:55:18.809 Dr. Hyder A. Khoja, Ph.D.: And I mean, this is the time where a middle-aged person, people who are already in the in these studies should bring this into into consideration. That is so important, especially these societies will help.
00:55:18.980 --> 00:55:21.209 Dr. Hyder A. Khoja, Ph.D.: and the promotion through conferences
00:55:21.270 --> 00:55:39.310 Dr. Hyder A. Khoja, Ph.D.: not necessarily a conference meant for only coma patient, I mean something related, an overall basis like in mental health, for sure. But if you look into general public mental health is just considered depression, anxiety, and wherever you open it they don't even think about anything else. Besides, anxiety and depression.
00:55:39.310 --> 00:55:53.049 Dr. Hyder A. Khoja, Ph.D.: anxiety and depression are the precursors that ignite and give you. If you are, doesn't you? Don't take care of it? It goes into that stage. So why don't you? Prevention is better than cure that we say we should do that in advance.
00:55:53.080 --> 00:55:58.090 Dr. Hyder A. Khoja, Ph.D.: Go through the school, and schools are the best places where we can also promote that.
00:55:58.520 --> 00:56:01.734 Dr. Hyder A. Khoja, Ph.D.: especially the medical schools. Right?
00:56:03.070 --> 00:56:30.579 Gaetano Lardieri FUNGGUY: So the area I mean all your areas that you're studying are fantastic. I think the area I'm really very interested in is the Tbi, right traumatic brain injury, because there's so much traumatic brain injury with American football and other sports and so on. So that's some future work. I'll be looking forward, coming out of your lab in the future. We got one more minute left. Anything more you want to say, hider, or how we get in touch with you or follow you.
00:56:31.490 --> 00:56:44.219 Dr. Hyder A. Khoja, Ph.D.: Yeah, I will be you know, my research is, you know, ongoing is it's not in really an infancy. At the moment it's gone through a little bit ahead. But I would really appreciate the scientific body medical body around
00:56:44.220 --> 00:57:08.630 Dr. Hyder A. Khoja, Ph.D.: who are listening that to to connect with me for collaboration for connections. This we can do as a team, a 1 person job is not a 1 person job. It requires a lot of funding for sure. It required a lot of, you know, a knowledge base expertise and the labs and all the institutions we are working in psychedelics. We are already into it. The John Hopkins University College of London, and many big Iv. Schools are already in.
00:57:08.640 --> 00:57:26.700 Dr. Hyder A. Khoja, Ph.D.: So why don't we take as an initiative of this kind of studies? Can also take care by them or by collaborating. So I would appreciate. If anyone wants to reach out. I can share my email now, if you would like, or maybe later. So my email address, personal email address is.
00:57:26.750 --> 00:57:31.750 Dr. Hyder A. Khoja, Ph.D.: Has koja@gmail.com spells like HAS.
00:57:31.860 --> 00:57:50.209 Dr. Hyder A. Khoja, Ph.D.: KHOJ. a@gmail.com. You can reach me there or through the Linkedin profile. You can just Google my name, Heather Ali Koja. It will pop up. You might able to read some publications that I'm doing. And maybe it's been a good time for connection, and we can work through together.
00:57:50.390 --> 00:57:54.399 Gaetano Lardieri FUNGGUY: Absolutely. I thank you. This has been fantastic. Thank you very much.
00:57:54.930 --> 00:58:08.380 Dr. Hyder A. Khoja, Ph.D.: I appreciate your time. for the happy spot in radio talk, New York, for inviting me and giving me chance to really navigate through and explain my journey. Thank you so very much.
00:58:08.530 --> 00:58:09.739 Gaetano Lardieri FUNGGUY: Thank you very much.
00:58:10.250 --> 00:58:31.219 JACK THOMAS: So I want to chime in. I am Jack Thomas. I'm 1 of the underwriters at the happy Spot, my partner Onchar. We have a vision of information. And we're so grateful for Gaetano and getting us started and having the information to educate and inform and integrate, educate, inform, and integrate. I've learned that in this community
00:58:31.220 --> 00:58:45.960 JACK THOMAS: so grateful harm reduction may roll into many others. But here's who I am, the happy spot where your physical reality, highest potential and soul's purpose are one. The future of work is happy. I help executives change employee behavior.
00:58:46.030 --> 00:58:49.590 JACK THOMAS: global behavior change one executive at a time.
00:58:49.670 --> 00:58:53.050 JACK THOMAS: Millennials and Gen. Z. Are redefining what work should be.
00:58:53.420 --> 00:59:01.609 JACK THOMAS: They've watched older generations grind themselves and have seen how it's impacted mental health relationships and even physical health. Now they're saying enough.
00:59:02.280 --> 00:59:04.769 JACK THOMAS: Look at that guy in New York shooting the CEO.
00:59:05.030 --> 00:59:09.130 JACK THOMAS: That generation is saying enough. It's our job to help change it.
00:59:09.460 --> 00:59:13.729 JACK THOMAS: I'm running productions right down the street from where that took place. It hits home.
00:59:14.650 --> 00:59:27.769 JACK THOMAS: They're holding the line when it comes to things like work-life balance, flexible schedules, fair pay protecting the mental health, doing meaningful work. Older generations, especially those in leadership, are going to have to catch up
00:59:28.440 --> 00:59:54.690 JACK THOMAS: risk losing talent or worse, be left behind. We have a choice. We need to decide whether we want to leave the next generation of body and soul crushing legacy or a life enhancing one. Dr. Heider. Thank you for channeling your energy. We'll be sharing through the octopus movement. New York City radio Gaetano. May you enjoy your time for the rest of the day. Thanks, everybody. Look forward to hearing from everyone to get it feedback.
00:59:56.290 --> 00:59:57.110 Dr. Hyder A. Khoja, Ph.D.: Thank you. Everybody.
01:00:22.690 --> 01:00:24.349 JACK THOMAS: You guys were great today. Thank you.
Talking Alternative Broadcasting
392 Central Park West Suite 17R - New York, NY 10025
Privacy Policy · Terms & Conditions
Thank You for Visiting TALKRADIO.NYC © 2022.
